DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Foundayo (orforglipron (oral, daily)) costs From ~$149/month via LillyDirect self-pay (dose-dependent), $25/month with insurance + savings card, or up to From ~$149/month self-pay (lowest dose) retail. Updated for 2026.
Same drug, different pricing channels. The spread is often $800-1000/month between cheapest and retail cash.
| Channel | Source | |
|---|---|---|
Cash-pharmacy + savings card Commercially insured with coverage — manufacturer copay card (GoodRx/SingleCare style discount otherwise). | ~$25 with commercial insurance + Foundayo savings cardBest value | Manufacturer savings card terms |
With insurance (covered, after PA) Commercial plan that covers the drug after prior authorization — copay depends on your tier. | $25/month – $150/month | Plan formulary copay tiers |
Retail / list (cash, no programs) Walk-in pharmacy price with no insurance, savings card, or manufacturer program. | From ~$149/month self-pay (lowest dose)List price | WAC / pharmacy list, LoseLab pricing desk |
Manufacturer cash — LillyDirect self-pay (dose-dependent) Anyone with a valid prescription who pays cash — no insurance required, valid in all 50 states. | From ~$149/monthLowest | LillyDirect |
We’ll email you the day it gets cheaper — no spam, unsubscribe anytime.
Foundayo launched with the lowest cash entry price of any FDA-approved GLP-1: LillyDirect self-pay starts around $149/month for the lowest dose. The honest caveat is that self-pay pricing is dose-dependent — Foundayo titrates from 0.8 mg up to a 17.2 mg maximum, and higher doses cost more — so budget against the dose you are likely to maintain, not the starter price. Because it is a daily tablet, there are also no pen/needle supplies to buy.
If your commercial plan covers Foundayo, the manufacturer savings card can bring eligible patients to as low as about $25/month, subject to the usual caps and terms. As a newly launched (April 2026) drug, formulary placement is still settling — expect prior authorization on most plans and check whether your plan has added it at all before assuming coverage. Copay-card rules are the same as other Lilly products: commercial insurance only, no government plans.
Three levers at launch: (1) the Foundayo savings card — as low as ~$25/month for eligible commercially insured patients (activate at foundayo.lilly.com); (2) LillyDirect self-pay — from ~$149/month for the lowest dose, no insurance needed; (3) a Lilly-announced Medicare Part D pathway at ~$50/month for eligible patients beginning as soon as July 1, 2026 — unusual for this category, and worth confirming with your plan since a manufacturer announcement is not a formulary listing.
Unusually for a weight-loss GLP-1, Lilly announced that eligible Medicare Part D patients may access Foundayo for about $50/month beginning as soon as July 1, 2026. Treat that as a manufacturer program announcement, not guaranteed plan coverage — Part D formularies decide listing plan-by-plan, and the statutory weight-loss exclusion still shapes this category. Confirm with your specific plan before counting on it.
State Medicaid coverage of Foundayo is still forming — the drug launched in April 2026, and state formulary additions lag launches by months. States that already cover weight-loss GLP-1s are the likeliest early adopters. Check your state formulary or our state-by-state Medicaid coverage pages for verified status.
The older oral GLP-1 (type 2 diabetes label; sometimes used off-label for weight). Strict empty-stomach dosing rules Foundayo does not have; pricing depends heavily on insurance.
$349–$499/month via LillyDirect vials — a weekly injection instead of a daily pill, but the highest trial efficacy in the class (~21% at 72 weeks in SURMOUNT-1 vs ~11-12% for orforglipron in ATTAIN-1). More weight loss per dollar if you tolerate injections.
$499/month via NovoCare direct — weekly injection, ~15% average loss in STEP-1. Also now available as an oral pill (oral Wegovy) if the tablet form is the draw.
Foundayo resets the entry price for FDA-approved GLP-1 therapy: from ~$149/month self-pay, ~$25/month for eligible commercially insured patients, and an announced ~$50/month Medicare pathway from July 2026. The trade-offs are dose-dependent self-pay costs as you titrate up and lower average weight loss than the injectables (~11-12% at 72 weeks in ATTAIN-1 vs ~21% for Zepbound). Cheapest per month in the class; not the most weight loss per dollar.
Read full Foundayo review →Pricing verified monthly against current manufacturer and pharmacy formularies. Coverage rules vary by plan — verify against your member portal before prescribing.